Bérubé Sylvie, Provencher Louise, Robert Jean, Jacob Simon, Hébert-Croteau Nicole, Lemieux Julie, Duchesne Thierry, Brisson Jacques
Unité de recherche en santé des populations, Hôpital St-Sacrement du Centre hospitalier affilié universitaire de Québec, 1050 Chemin Sainte-Foy, Québec, Qc, Canada, G1S 4L8.
Breast Cancer Res Treat. 2007 Dec;106(3):419-31. doi: 10.1007/s10549-007-9503-1. Epub 2007 Feb 1.
Breast cancer mortality has been declining in many countries including Canada because of improvements in survival. This study attempts to explain observed trends in breast cancer survival with special attention given to the role of improvements in early detection and treatment.
This study is based on 4,312 women diagnosed with primary invasive breast carcinoma treated in a Canadian breast center between 1976 and 2000 and followed to the end of 2001. Observed and relative survival rates were calculated. Multivariate relative survival regression models were used to assess trends in breast cancer survival over the study period.
The proportion of women with small tumors (< or = 10 mm) was higher in late 1990s, while that of women with regional involvement was lower compared to earlier periods. Adjuvant chemotherapy or endocrine therapy use increased steadily from 6.6% to 84.0% during the study period. Five-year relative survival rates ranged between 82.1% and 83.7% between 1976 and 1990, and increased thereafter to reach 87.6% in 1991-95, and 92.1% in 1996-2000. During the first five years after diagnosis, women diagnosed in 1991-95 and 1996-2000 experienced a reduction in breast cancer mortality of 28% (Relative Risk (RR)= 0.72; 95% CI: 0.59-0.89) and 49% (RR = 0.51; 95% CI: 0.39-0.68) respectively compared to women diagnosed in 1976-90. Improvement in breast cancer survival in 1990's could not be explained by characteristics of women, biology of the tumor, advancements in early detection and type of initial treatments.
A substantial increase in breast cancer survival was observed in the 1990s but the reasons for this improvement remain elusive. Better knowledge of these reasons could help not only to further reduce the burden related to breast cancer but also the burden related to other major cancer sites.
由于生存率的提高,包括加拿大在内的许多国家乳腺癌死亡率一直在下降。本研究试图解释观察到的乳腺癌生存趋势,特别关注早期检测和治疗改善所起的作用。
本研究基于1976年至2000年期间在加拿大一家乳腺中心接受治疗的4312名原发性浸润性乳腺癌女性患者,并随访至2001年底。计算观察到的生存率和相对生存率。使用多变量相对生存回归模型来评估研究期间乳腺癌生存趋势。
20世纪90年代后期,肿瘤较小(≤10毫米)的女性比例较高,而区域受累女性的比例与早期相比更低。在研究期间,辅助化疗或内分泌治疗的使用率从6.6%稳步上升至84.0%。1976年至1990年期间,五年相对生存率在82.1%至83.7%之间,此后有所上升,在1991 - 1995年达到87.6%,在1996 - 2000年达到92.1%。在诊断后的头五年里,与1976 - 1990年诊断的女性相比,1991 - 1995年和1996 - 2000年诊断的女性乳腺癌死亡率分别降低了28%(相对风险(RR)= 0.72;95%置信区间:0.59 - 0.89)和49%(RR = 0.51;95%置信区间:0.39 - 0.68)。20世纪90年代乳腺癌生存率的提高无法用女性特征、肿瘤生物学、早期检测进展和初始治疗类型来解释。
20世纪90年代观察到乳腺癌生存率大幅提高,但这种改善的原因仍然不明。更好地了解这些原因不仅有助于进一步减轻与乳腺癌相关的负担,也有助于减轻与其他主要癌症部位相关的负担。